drugset / Trial / NCT00911586

Pharmacokinetic Study to Determine Time to Steady-state

NCT00911586

Phase 2 Completed 15 enrolled Clarus Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.

Timeline

Start
2009-07
Primary completion
2009-09
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Undecanoate Small molecule 200 mg Oral

Indications